PRE-CONFERENCE WORKSHOP DAY

Tuesday, December 10, 2024

Workshop A | 9:00 am - 12:00 pm

Interrogating & Optimizing Covalent Library Design to Improve the Generation of Viable Hits that Efficiently Engage the Target & Display Improved Safety Profiles

Sebastian Essig
Director & Group Leader, Chemical Biology
Bayer

 

Comprehensive library design is crucial for identifying viable hits and warheads with the potential to advance into potent and selective covalent drugs. Creating effective covalent libraries, including optimizing molecular size and diversity, achieving target specificity, and balancing electrophile reactivity poses obstacles in ensuring libraries are both synthetically feasible and efficient in target engagement, while avoiding off-target interactions. This workshop will equip you with strategies to overcome these hurdles by leveraging state-of-the-art methodologies for respective screening platforms and insights from recent advancements in covalent drug discovery.

This workshop will discuss:

  • What is the optimal library size for balancing build capacity and screening efficiency?
  • How can you determine the appropriate molecular size and diversity for your library? How can we leverage different screening techniques to broaden this?
  • How to inform which electrophiles should be incorporated, and how reactive should they be to minimize off-target toxicities
  • How can you ensure the synthetic ease of library compounds?
  • How to ensure your library is enabling effective engagement with your targets of interest

Workshop B | 1:00 - 4:00 pm

Fast-Track Target Validation to De-Risk Covalent Drug Discovery Pipelines in Oncology & Beyond

Jamie Rice
Senior Director & Head of Discovery Biology
Covant Therapeutics

 

From undrugged oncology targets to immunology and CNS indications with unmet patient need, the renaissance in covalent modalities continues to present huge promise in expanding the paradigm of druggable targets. However unlocking difficultto-drug proteins and establishing pipelines in pursuit of first-in-class drugs remains no easy feat, with persistent challenges in distinguishing tractable targets, optimizing target engagement, and minimizing off-target effects. Tackling these bottlenecks head-first, this workshop will address the critical target identification, validation and chemical biology challenges allowing you to de-risk your future pipeline.

This workshop will address:

  • How to de-risk and assess the tractability of covalency for different targets
  • What are the key criteria for selecting covalent drug targets? And how does this differ between indications?
  • How to leverage advanced screening technologies to enhance target identification
  • How to effectively validate target engagement and through what methodologies
  • What role does structural biology play in understanding target interactions?
  • Debating the best practices for optimizing target specificity and selectivity

ACCESS THE FULL PROGRAM

Explore three days of sessions and workshops, the full 22+ speaker faculty, and more by downloading your copy of the event guide.

Rosie favicons (6)